Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

AMGEN INC Director's Dealing 2020

Apr 14, 2020

29819_dirs_2020-04-13_87bff617-e133-44f4-92d1-1f24a10cf721.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AMGEN INC (AMGN)
CIK: 0000318154
Period of Report: 2020-04-13

Reporting Person: Bradway Robert A (Director, Chairman, CEO and President)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2020-04-13 Common Stock M 43000 $58.43 Acquired 540027 Direct
2020-04-13 Common Stock F 28511 $218.21 Disposed 511516 Direct
2020-04-13 Common Stock M 84000 $58.43 Acquired 595516 Direct
2020-04-13 Common Stock F 55695 $218.21 Disposed 539821 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2020-04-13 Nqso (Right to Buy) $58.43 M 43000 Disposed 2020-04-26 Common Stock (43000) Direct
2020-04-13 Nqso (Right to Buy) $58.43 M 84000 Disposed 2020-04-26 Common Stock (84000) Direct

Footnotes

F1: Non-market exercise of a total of 127,000 stock options expiring April 26, 2020 wherein 84,206 shares, in the aggregate, issuable pursuant to the exercise of these options were withheld by the Company to cover the option exercise price and tax withholding, with the remaining shares delivered to the reporting person.

F2: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 4,784 RSUs which vest on 5/3/2020; 9,890 RSUs which vest in installments of 4,871 on 5/1/2020 and 5,019 on 5/1/2021; 14,087 RSUs which vest in installments of 4,648 on 4/27/2020, 4,649 on 4/27/2021 and 4,790 on 4/27/2022; and 15,791 RSUs which vest in two installments of 5,211 on 5/3/2021 and 5/3/2022 and one installment of 5,369 on 5/3/2023. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3: These shares include 2,730 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.